Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial - PubMed

4 hours ago

This phase 2a randomized clinical trial investigated the effects of semaglutide versus placebo on smoking-related outcomes in adults with daily cigarette use.
The study enrolled 45 participants, with 24 randomized to either placebo or semaglutide treatment over nine weeks.
Primary outcomes, including laboratory measures of smoking resistance and cigarettes per day, did not show significant treatment-by-time interactions.
However, supplementary analyses indicated semaglutide significantly reduced laboratory smoking compared to placebo after treatment.
Semaglutide significantly reduced cigarette craving and body weight over the treatment weeks compared to placebo.
Explorative analyses suggested potential effects on withdrawal symptoms.
The trial concluded that semaglutide monotherapy did not significantly increase smoking resistance or reduce weekly cigarette counts but reduced craving and weight, warranting larger trials for further evaluation.

Hasty Briefsbeta